Evaxion presents a new source of ai-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients

Copenhagen, denmark, march 23, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the discovery and development of ai-powered immunotherapies today announces that it has developed a new proprietary ai platform technology observ™ to identify a new source of targets for personalized cancer therapy, potentially enabling treatment of patients that are currently considered unresponsive to cancer immunotherapy.
EVAX Ratings Summary
EVAX Quant Ranking